{"id":"placebo-to-aprepitant","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL4303169","moleculeType":"Small molecule","molecularWeight":"534.43"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Aprepitant works by blocking the action of substance P, a natural substance that causes nausea and vomiting. By blocking substance P, aprepitant reduces the frequency and severity of nausea and vomiting associated with chemotherapy and radiation therapy.","oneSentence":"Aprepitant is a substance P/neurokinin 1 (NK1) receptor antagonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:40.253Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)"},{"name":"Prevention of postoperative nausea and vomiting (PONV)"}]},"trialDetails":[{"nctId":"NCT04649229","phase":"PHASE4","title":"Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3","status":"COMPLETED","sponsor":"Yale University","startDate":"2021-05-27","conditions":"Heart Failure","enrollment":46},{"nctId":"NCT07248280","phase":"PHASE3","title":"Adding Aprepitant to a Multimodal Strategy for the Prevention of Postoperative Nausea and Vomiting in High-risk Outpatient Surgical Patients","status":"RECRUITING","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2026-02-27","conditions":"Nausea and Vomiting, Postoperative, Prevention","enrollment":260},{"nctId":"NCT07371728","phase":"PHASE4","title":"Effect of Aprepitant on Post-operative Nausea and Vomiting in Otologic Surgery","status":"NOT_YET_RECRUITING","sponsor":"Sir Mortimer B. Davis - Jewish General Hospital","startDate":"2026-06-01","conditions":"Otologic Disease","enrollment":100},{"nctId":"NCT06932107","phase":"PHASE3","title":"Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting","status":"COMPLETED","sponsor":"Qilu Pharmaceutical (Hainan) Co., Ltd.","startDate":"2024-02-02","conditions":"Postoperative Nausea and Vomiting","enrollment":518},{"nctId":"NCT03578081","phase":"PHASE3","title":"Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2018-11-20","conditions":"Malignant Neoplasm","enrollment":690},{"nctId":"NCT05773950","phase":"NA","title":"Triple Therapy of Dexamethasone, Palonosetron, and Fosaprepitant As PONV Prevention","status":"ENROLLING_BY_INVITATION","sponsor":"Samsung Medical Center","startDate":"2023-08-18","conditions":"Postoperative Nausea and Vomiting, Gynecologic Surgical Procedures, Laparoscopy","enrollment":144},{"nctId":"NCT06357234","phase":"PHASE2","title":"Aprepitant Treatment to Prevent Postoperative Nausea and Vomiting in Children Undergoing Scoliosis Surgery","status":"RECRUITING","sponsor":"IWK Health Centre","startDate":"2025-03-17","conditions":"Spinal Fusion, Nausea and Vomiting, Postoperative, Anesthesia","enrollment":100},{"nctId":"NCT05189756","phase":"PHASE4","title":"Dual-dose Aprepitant to Reduce Postoperative Nausea and Vomiting After Laparoscopic Bariatric Surgery.","status":"TERMINATED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2022-03-17","conditions":"Postoperative Nausea and Vomiting, Bariatric Surgery","enrollment":71},{"nctId":"NCT06593782","phase":"PHASE2","title":"Evaluating the Efficacy and Safety of HSK21542 Injection in Chemotherapy-induced Nausea and Vomiting","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2024-09-16","conditions":"Nausea and Vomiting, Chemotherapy-Induced","enrollment":180},{"nctId":"NCT06543966","phase":"PHASE3","title":"Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting","status":"NOT_YET_RECRUITING","sponsor":"CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.","startDate":"2024-10-28","conditions":"Post-operative Nausea and Vomiting (PONV)","enrollment":486},{"nctId":"NCT03674294","phase":"PHASE3","title":"Aprepitant Triple Therapy for the Prevention of CINV in Nondrinking and Young Women Who Received Moderately Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2015-08-04","conditions":"Gastrointestinal Neoplasms, Chemotherapy-induced Nausea and Vomiting","enrollment":248},{"nctId":"NCT02130687","phase":"NA","title":"Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2014-06","conditions":"Type 2 Diabetes Mellitus, Hypertension","enrollment":106},{"nctId":"NCT01661335","phase":"PHASE3","title":"Efficacy of Aprepitant (Emend®) in Children","status":"COMPLETED","sponsor":"University of Oklahoma","startDate":"2012-06-01","conditions":"Nausea, Vomiting, Childhood Cancer","enrollment":19},{"nctId":"NCT01176591","phase":"PHASE2","title":"HBPL Study of the Impact of the NK1 Antagonist Aprepitant","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2010-09","conditions":"Cocaine Dependence, Alcohol Dependence","enrollment":13},{"nctId":"NCT02161991","phase":"PHASE3","title":"Aprepitant for Chemotherapy Induced Nausea and Vomiting in Chinese Advanced Non-small Cell Lung Cancers","status":"COMPLETED","sponsor":"Hunan Province Tumor Hospital","startDate":"2014-02-01","conditions":"Carcinoma, Non-small Cell Lung","enrollment":244},{"nctId":"NCT01505179","phase":"NA","title":"The Effects of Ranolazine on Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2011-02","conditions":"Heart Failure With Preserved Ejection Fraction","enrollment":10},{"nctId":"NCT01697579","phase":"PHASE2","title":"Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-13","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":240},{"nctId":"NCT02519842","phase":"PHASE3","title":"Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-09-14","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":75},{"nctId":"NCT02989467","phase":"PHASE1","title":"Effects of Aprepitant on Satiation, Gastric Volume, Gastric Accommodation and Gastric Emptying","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2017-01-27","conditions":"Healthy","enrollment":27},{"nctId":"NCT01362530","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-09-13","conditions":"Chemotherapy Induced Nausea and Vomiting","enrollment":307},{"nctId":"NCT01732458","phase":"PHASE2","title":"A Study to Evaluate Aprepitant for the Prevention of Post-Operative Nausea and Vomiting in Children (MK-0869-219)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-02-12","conditions":"Post-operative Nausea, Post-operative Vomiting","enrollment":229},{"nctId":"NCT01636947","phase":"PHASE4","title":"A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-12","conditions":"Nausea, Vomiting","enrollment":494},{"nctId":"NCT01594749","phase":"PHASE3","title":"Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-09-24","conditions":"Chemotherapy-Induced Nausea and Vomiting (CINV)","enrollment":1015},{"nctId":"NCT00781768","phase":"PHASE4","title":"Odansetron and Dexamethasone Alone vs. Odansetron, Dexamethason and Apreptant to Prevent Nausea","status":"COMPLETED","sponsor":"Loyola University","startDate":"2003-08","conditions":"Nausea, Vomiting","enrollment":181},{"nctId":"NCT00999544","phase":"NA","title":"Aprepitant Effects on Oxycodone Response","status":"COMPLETED","sponsor":"Sharon Walsh","startDate":"2009-10","conditions":"Narcotic Abuse","enrollment":9},{"nctId":"NCT00952341","phase":"PHASE3","title":"Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-08-25","conditions":"Chemotherapy-induced Nausea and Vomiting (CINV)","enrollment":421},{"nctId":"NCT00337727","phase":"PHASE3","title":"Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-01-01","conditions":"Chemotherapy-Induced Nausea and Vomiting","enrollment":848},{"nctId":"NCT00900068","phase":"","title":"Blood Samples From Patients on a Clinical Trial to CINV During HSCT","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2008-08","conditions":"Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor","enrollment":9},{"nctId":"NCT00248547","phase":"NA","title":"Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant","status":"COMPLETED","sponsor":"OHSU Knight Cancer Institute","startDate":"2004-05","conditions":"Cancer","enrollment":40},{"nctId":"NCT00428519","phase":"PHASE1","title":"Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2007-01","conditions":"HIV Infections","enrollment":30},{"nctId":"NCT01432015","phase":"PHASE4","title":"Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting","status":"COMPLETED","sponsor":"Gynecologic Oncology Associates","startDate":"2011-09","conditions":"Ovarian Cancer, Uterine Cancer","enrollment":20},{"nctId":"NCT02550119","phase":"NA","title":"Dolasetron Mesylate and Dexamethasone With or Without Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancy","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2006-04-19","conditions":"Malignant Digestive System Neoplasm, Nausea and Vomiting","enrollment":19},{"nctId":"NCT01300988","phase":"PHASE1","title":"Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals. 375 mg Dose","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2010-12","conditions":"HIV Infection","enrollment":18},{"nctId":"NCT00572572","phase":"PHASE3","title":"Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors","status":"COMPLETED","sponsor":"Hoosier Cancer Research Network","startDate":"2007-12","conditions":"Germ Cell Tumors","enrollment":69},{"nctId":"NCT01205503","phase":"PHASE2","title":"Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release","status":"COMPLETED","sponsor":"Mara Chambers","startDate":"2010-09","conditions":"Breast Cancer, Non-Hodgkin's Lymphoma","enrollment":32},{"nctId":"NCT00896038","phase":"PHASE2","title":"The Effect of NK1R Antagonism on Alcohol Craving and PTSD Symptoms in Alcohol Dependent Patients With PTSD","status":"COMPLETED","sponsor":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","startDate":"2009-05","conditions":"Alcoholism, Alcohol Dependence, Posttraumatic Stress Disorder","enrollment":58},{"nctId":"NCT02357693","phase":"PHASE4","title":"Neurokinin Receptor Antagonist Associated to Ondansetron in PONV","status":"COMPLETED","sponsor":"Instituto do Cancer do Estado de São Paulo","startDate":"2015-02","conditions":"Postoperative Nausea and Vomiting","enrollment":90},{"nctId":"NCT00990821","phase":"PHASE1","title":"A Study to Investigate the Safety and Tolerability of MK-0517 in Healthy Subjects (MK-0517-012)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-01","conditions":"Chemotherapy-Induced Nausea and Vomiting, Postoperative Nausea and Vomiting","enrollment":188},{"nctId":"NCT00736073","phase":"NA","title":"A Trial of Aprepitant For Prevention of Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis","status":"COMPLETED","sponsor":"Duke University","startDate":"2007-08","conditions":"Pancreatitis","enrollment":73},{"nctId":"NCT02226601","phase":"NA","title":"Aprepitant to Mitigate Opioids' Cognitive Side Effects","status":"UNKNOWN","sponsor":"University of Arizona","startDate":"2014-10","conditions":"Cognitive Dysfunction","enrollment":50},{"nctId":"NCT02431286","phase":"PHASE4","title":"Palonosetron Associated to Aprepitant in Prophylaxis of PONV","status":"UNKNOWN","sponsor":"Instituto do Cancer do Estado de São Paulo","startDate":"2014-10","conditions":"Postoperative Nausea and Vomiting","enrollment":90},{"nctId":"NCT01074697","phase":"PHASE3","title":"Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin","status":"COMPLETED","sponsor":"Odense University Hospital","startDate":"2010-04","conditions":"Nausea, Vomiting, Genital Neoplasms, Female","enrollment":246},{"nctId":"NCT02407600","phase":"PHASE2","title":"Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy","status":"UNKNOWN","sponsor":"Ajeet Gajra","startDate":"2015-04","conditions":"Non-small Cell Lung Cancer, Vomiting, Nausea","enrollment":150},{"nctId":"NCT01402024","phase":"PHASE3","title":"Study to Evaluate Anti-emetic Effect of Aprepitant Versus Placebo in Children and Adolescent Receiving Chemotherapy","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences","startDate":"2011-08","conditions":"Chemotherapy Induced Nausea and Vomiting","enrollment":96},{"nctId":"NCT00080444","phase":"PHASE3","title":"Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-04","conditions":"Vomiting","enrollment":50},{"nctId":"NCT00717054","phase":"NA","title":"Comparison of Aprepitant Versus Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting","status":"COMPLETED","sponsor":"Drexel University","startDate":"2008-02","conditions":"Nausea, Vomiting","enrollment":115},{"nctId":"NCT00659737","phase":"NA","title":"Comparison of Oral Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting","status":"COMPLETED","sponsor":"Drexel University College of Medicine","startDate":"2008-04","conditions":"Nausea, Vomiting","enrollment":115},{"nctId":"NCT00738621","phase":"PHASE4","title":"Combination Antiemetic Regimen for Prevention of PONV in Breast Surgery Patients","status":"COMPLETED","sponsor":"Scott and White Hospital & Clinic","startDate":"2008-07","conditions":"Postoperative Nausea and Vomiting","enrollment":100},{"nctId":"NCT01474915","phase":"PHASE4","title":"Aprepitant Versus Ondansetron in Preoperative Triple-therapy Treatment of Nausea and Vomiting","status":"COMPLETED","sponsor":"Sergio Bergese","startDate":"2007-06","conditions":"Postoperative Nausea and Vomiting (PONV), Nausea","enrollment":122},{"nctId":"NCT01393288","phase":"NA","title":"Developing Individualized Strategies to Prevent Nausea and Vomiting","status":"WITHDRAWN","sponsor":"University of California, San Francisco","startDate":"2013-11","conditions":"Postoperative Nausea and Vomiting, Genetic Polymorphisms","enrollment":""},{"nctId":"NCT00699894","phase":"NA","title":"Aprepitant PO vs Ondansetron IV for Prevention of Postoperative Nausea and Vomiting","status":"WITHDRAWN","sponsor":"Northwell Health","startDate":"2008-06","conditions":"Postoperative Nausea and Vomiting","enrollment":""},{"nctId":"NCT01580423","phase":"NA","title":"The Role of Substance P on Perception of Breathlessness During Resistive Load Breathing","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2012-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":16},{"nctId":"NCT01897337","phase":"PHASE4","title":"The Effect of Combining Aprepitant With Ondansetron in High-risk Patients for Postoperative Nausea and Vomiting","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2012-06","conditions":"Postoperative Nausea and Vomiting","enrollment":125},{"nctId":"NCT00659945","phase":"PHASE4","title":"Aprepitant for PONV Prophylaxis in Outpatient Plastic Surgery","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2008-06","conditions":"Postoperative Nausea and Vomiting","enrollment":150},{"nctId":"NCT01101529","phase":"PHASE2","title":"Treatment of Chemotherapy-induced Nausea and Vomiting","status":"COMPLETED","sponsor":"Uppsala University Hospital","startDate":"2010-05","conditions":"Nausea, Vomiting","enrollment":90},{"nctId":"NCT00212602","phase":"PHASE2","title":"ONO-7436 Phase II Study in Japan","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2005-08","conditions":"Malignant Tumor","enrollment":420},{"nctId":"NCT00888329","phase":"PHASE4","title":"Aprepitant for Prevention of Postoperative Nausea and Vomiting in Elective Hysterectomy","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2007-07","conditions":"Postoperative Nausea and Vomiting","enrollment":256},{"nctId":"NCT00956215","phase":"NA","title":"Decreasing the Incidence of Post-Operative Nausea and Vomiting (PONV) in Bariatric Patients","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2010-05","conditions":"Nausea, Vomiting","enrollment":125},{"nctId":"NCT00571168","phase":"PHASE3","title":"Efficacy and Safety of Aprepitant in Subjects With Multiple Myeloma During and After High-dose Chemotherapy","status":"UNKNOWN","sponsor":"Heidelberg University","startDate":"2005-07","conditions":"Multiple Myeloma","enrollment":362},{"nctId":"NCT00415103","phase":"PHASE4","title":"AMENO-2: Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2006-11","conditions":"Leukemia, Lymphoma","enrollment":196},{"nctId":"NCT00835965","phase":"NA","title":"Oral Aprepitant and Lower Dose Dexamethasone Versus Aprepitant Alone for Preventing Postoperative Nausea and Vomiting (PONV) After Elective Laparoscopic Surgeries","status":"UNKNOWN","sponsor":"Main Line Health","startDate":"2009-02","conditions":"Nausea, Vomiting","enrollment":50},{"nctId":"NCT00726960","phase":"PHASE1","title":"Ability of Aprepitant to Block Opioid Reward in Non-Dependent Opiate Abusers","status":"UNKNOWN","sponsor":"Karolinska University Hospital","startDate":"2008-01","conditions":"Opioid-Related Disorders, Heroin Dependence, Substance-Related Disorders","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":123,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Matching placebo to aprepritant was administered as a single oral dose on Day 1 between 1 and 3 hours prior to expected induction of anesthesia."],"phase":"phase_3","status":"active","brandName":"placebo to aprepitant","genericName":"placebo to aprepitant","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aprepitant is a substance P/neurokinin 1 (NK1) receptor antagonist. Used for Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV), Prevention of postoperative nausea and vomiting (PONV).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}